NCT06147518View on ClinicalTrials.gov

To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis

NANot yet recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Compensated CirrhosisDecompensated Cirrhosis
Interventions
DRUG

Metformin

Metformin: 1.5g/d CTPA,1g/d CTPB

DRUG

Sitagliptin

Sitagliptin: Assess HbA1c/HBSG at 8 weeks, increase sitagliptin to 100 mg if HbA1c\>7%

DRUG

Dapagliflozin

Assess HbA1c/HBSG at 8 weeks, increase Dapagliflozin to 10 mg if HbA1c\>7%

Trial Locations (1)

110070

Dr Rakesh Kumar Jagdish, New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT06147518 - To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis | Biotech Hunter | Biotech Hunter